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A 3-month, Multicenter, Randomized, Open-label 
Study to Evaluate the Impact on Wound Healing of 
the Early (vs Delayed) Introduction of Everolimus 
in De Novo Kidney Transplant Recipients, With 
a Follow-up Evaluation at 12 Months After 
Transplant (NEVERWOUND Study)
Tommaso Maria Manzia, PhD,1 Mario Carmellini, Prof,2 Paola Todeschini, PhD,3 Antonio Secchi, Prof,4  
Silvio Sandrini, PhD,5 Enrico Minetti, Prof,6 Lucrezia Furian, Prof,7 Gionata Spagnoletti, PhD,8  
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INTRODUCTION
In kidney transplantation (KT), the introduction of new 
immunosuppressive agents may offer the opportunity to 
reduce adverse events (AEs) and personalize the therapy, 
while maintaining a good feasibility and efficacy. The 
introduction of mycophenolic acid (MPA) and mammalian 
target of rapamycin inhibitors (mTORis) led, in selected 
patients, to the reduction or elimination of calcineurin 
inhibitors (CNIs) in early post-KT.1-5 Everolimus (EVR) 
(Certican; Novartis Pharma AG, Basel, Switzerland) is a 
Original Clinical Science—General
Background. The risk of wound healing complications (WHCs) and the early use of mammalian target of rapamycin inhibi-
tors after kidney transplantation (KT) have not been fully addressed. Methods. The NEVERWOUND study is a 3-month, 
multicenter, randomized, open-label study designed to evaluate whether a delayed (ie, 28 ± 4 d posttransplant) immunosup-
pression regimen based on everolimus (EVR) reduces the risk of WHC versus EVR started immediately after KT. Secondary 
endpoints were treatment failure (biopsy-proven acute rejection, graft loss, or death), delayed graft function, patient and graft 
survival rates, and renal function. Results. Overall, 394 KT recipients were randomized to receive immediate (N = 197) or 
delayed (N = 197) EVR after KT. At 3 months, WHC-free rates in the immediate EVR versus delayed EVR arm, considering 
the worst- and best-case scenario approach, were 0.68 (95% confidence interval [CI], 0.62-0.75) versus 0.62 (95% CI, 0.55-
0.68) (log-rank P = 0.56) and 0.70 (95% CI, 0.64-0.77) versus 0.72 (95% CI, 0.65-0.78) (log-rank P = 0.77), respectively. 
The 3- and 12-month treatment failure rates, delayed graft function and renal function, and patient and graft survival were 
not different between the arms. Conclusions. The early introduction of EVR after KT did not increase the risk of WHC, 
showing good efficacy and safety profile.
(Transplantation 2020;104: 374–386).
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mTORi immunosuppressant drug with antiproliferative 
properties that reduces growth factor–stimulated lympho-
cyte proliferation.6,7 In the experimental model and KT 
human trials, EVR showed good safety and efficacy with an 
acceptable tolerability,8-11 while reducing vascular smooth 
muscle cells proliferation6 and neointimal growth12-15 and 
leading to a reduction in graft arteriosclerosis.16
Several studies suggested that Sirolimus, an mTORi 
drug, was associated with an increased rate of wound heal-
ing complications (WHCs) after solid organ transplanta-
tion,17-23 an effect potentially related to the inhibition of 
the activation and proliferation of fibroblast cells. On the 
contrary, even if the evidence is still scarce, EVR did not 
show inferiority versus other immunosuppression (IS)24,25 
and only the drug exposure seems to be related with WHC, 
especially in severely obese recipients.26,27
In the CALLISTO study,28 a 12-month randomized 
multicenter trial, KT patients at risk of delayed graft 
function (DGF) were randomized to receive EVR either 
immediately after KT or in a delayed setting. Composite 
endpoints were DGF, biopsy-proven acute rejection 
(BPAR), death, and WHC. The authors eventually specify 
that the immediate introduction of EVR was not associ-
ated with any disadvantage in terms of graft recovery or 
wound healing.
Considering the small population (ie, 139 randomized 
patients) of the CALLISTO study and the sample size esti-
mation (calculated for the composite endpoint)—as well 
as the lack of any randomized trial on mTORi fitted for 
WHC only—the present study was designed with the aim 
of evaluating whether the delayed administration of EVR 
(ie, 28 ± 4 d posttransplant) reduces the risk of WHC in de 
novo KT recipients.
MATERIALS AND METHODS
Study Design
The NEVERWOUND study was a 3-month, multi-
center, randomized, prospective, open-label study with an 
observational follow-up of 12 months, conducted in 22 
Italian kidney transplant centers from November 2011 
to December 2015 with the goal of evaluating whether a 
delayed (ie, 28 ± 4 d posttransplant) EVR-based IS regimen 
reduces the risk of WHC versus EVR started immediately 
after KT.
During the screening (day −2 to day 0), patients were 
assessed for eligibility for the study. At day 0, all patients 
underwent KT and started the induction treatment as per 
clinical practice. In all cases, the transplantation consisted 
in the standard pelvic operation, with heterotopic extra-
peritoneal placement of the graft and ureteroneocystos-
tomy according to Lich et al29 and Gregoir.30 At baseline 
(day 1 to day 2), transplanted patients eligible for the 
study were randomized (ratio, 1:1) to 1 of the 2 follow-
ing treatment arms: immediate EVR (IE) or delayed EVR 
(DE) (Figure 1) via a Web-based system and stratified by 
age at transplant (≤60 or >60) and pretransplant diabetes 
mellitus status.31
Upon completion of the 3-month treatment period 
(CORE phase study), patients entered a 9-month obser-
vational follow-up period, where they were treated as per 
local clinical practice. During the follow-up visit performed 
12 months (−1/+6 mo) after KT, information was collected 
on patient and graft survival, renal function, acute rejec-
tion, malignancies, wound assessment, new-onset diabetes 
mellitus, serum creatinine, and blood levels of EVR and 
cyclosporine A (CsA).
FIGURE 1. Study design. C0, immunosuppression blood levels, before morning dose; C2, immunosuppression blood levels, 2 h after 
morning dose; CsA, cyclosporine A; D, day; DE, delayed everolimus; EVR, everolimus; FPIA, fluorescence polarization immunoassay; 
FUP, follow-up; HPLC, high-performance liquid chromatography; IE, immediate everolimus; M, month; Myf, myfortic; scr, screening.
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The study complied with the ICH Harmonized Tripartite 
Guidelines for Good Clinical Practice and the Declaration 
of Helsinki and its amendments. A written informed con-
sent was obtained from all patients, and each center’s ethi-
cal committee approved the study.
Treatment Regimens
In the IE, EVR was started within 48 hours after graft 
reperfusion, at the starting dose of 0.75 mg BID, adjusted 
to target EVR trough level at 0 hour (immunosuppression 
blood levels, before morning dose [C0]) to reach a range 
of 3–8 ng/mL (using the high-performance liquid chro-
matography method) or 5–10 ng/mL (using the fluores-
cence polarization immunoassay method); CsA (Neoral; 
Novartis Pharma AG, Basel, Switzerland) was adminis-
tered BID per os within 48 hours of graft reperfusion, at a 
starting dose of 4 mg/kg/d. The dose was then adjusted to 
reach and maintain CsA immunosuppression blood levels 
2 h after morning dose (C2) between 500 and 700 ng/mL. 
When the EVR target level was reached, CsA was tapered 
up to reach C2 levels between 250 and 450 ng/mL during 
month 2 and between 200 and 400 ng/mL up to month 3.
In the DE, MPA (Myfortic; Novartis Pharma AG, Basel, 
Switzerland) was administered within 48 hours after graft 
reperfusion, at the dose of 720 mg BID. At 28 ± 4 days 
after KT, MPA was discontinued and EVR was started at 
0.75 mg BID to reach and maintain C0 3–8 ng/mL (high-
performance liquid chromatography method) or 5–10 ng/
mL (fluorescence polarization immunoassay method). CsA 
was administered BID per os within 48 hours of graft rep-
erfusion, at a starting dose of 6–8 mg/kg/d. The dose was 
adjusted to reach C2 levels of 700–1000 ng/mL until day 
28 ± 4. The dose was then tapered up to reach the same IE 
arm C2 levels.
Intravenous prednisone (or equivalent) was adminis-
tered perioperatively, and oral corticosteroids were started 
the day after, at 20 mg/d, and then tapered according to the 
center’s clinical practice. Induction therapy was adminis-
tered, as per local clinical practice (namely IL2 receptor 
antibodies [Ab-IL2-R] or antithymocyte globuline [ATG]).
Inclusion criteria for the study were as follows: all adult 
(>18 y) male or female patients who had received first or 
second single KT from deceased donor or living related 
were eligible for the study.
Patients were excluded in the following cases: recipi-
ents of multiple organ transplants, including 2 kidneys; 
women of childbearing potential, unless they were using 
2 birth control methods; pregnant or nursing (lactating) 
women; recipients with historical or current peak panel 
reactive antibodies >50% or unacceptable human leuko-
cyte antigen(s), platelets <75000/mm3, absolute neutrophil 
count <1500/mm3, leukocytes <2500/mm3, or hemoglobin 
<7 g/dL; symptoms of significant somatic or mental illness; 
history of malignancies within the past 5 years; human 
immunodeficiency virus (HIV) positivity; evidence of severe 
liver disease; severe active infections; evidence of drug or 
alcohol abuse; or body mass index (BMI) >30 kg/m2.
Primary Endpoint
The primary objective of the study was to evaluate—
during the treatment period (90 ± 4 postoperative days)—
whether the delayed administration of EVR in de novo KT 
recipients reduced the risk of WHC versus the immediate 
administration.
WHCs were defined as fluid collection, including hema-
toma and lymphocele (defined as serum >5 cm fluid collec-
tions evaluated by ultrasound [assessed at 14 ± 4, 28 ± 4, 
90 ± 4, and 360 ± 30 postoperative days]), requiring or not 
intervention; prolonged lymphatic drainage (ie, lymphor-
rea) >150 mL/24 h at 7 postoperative days; wound dehis-
cence, wound infection, and incisional hernia (evaluated 
after 3 and 12 mo).
Secondary Endpoints and AEs
The secondary objectives were as follows: treatment 
failure rate (composite endpoint: BPAR [graded accord-
ing to Banff 97 criteria], graft loss, death); death-censored 
graft survival rate; graft survival rate; patient survival 
rate; incidence and duration (days) of DGF (arbitrar-
ily defined as the need of dialysis in the first week after 
transplant); renal function, through estimated glomerular 
filtration rate (estimated glomerular filtration rate–mod-
ification of diet in renal diseases formula); proteinuria 
(>1000 mg/24 h or >1.0 protein/creatinine in a spot urine 
sample); safety; and tolerability (incidence of AEs, serious 
AEs, infections).
Sample Size
A 2-group continuity-corrected chi-square test with a 
0.05 2-sided significance level had a 90% power to detect 
the difference between a group IE percentage of 0.65 and 
DE percentage of 0.80 (odds ratio, 2.15) when the sam-
ple size in each arm was 198. Three hundred ninety-six 
patients were therefore enrolled.
Study Population
The following populations were defined in the study:
Intent-to-treat population consisting in all the randomized 
patients who were treated.
Safety population consisting in all the randomized patients 
who were treated and had ≥1 safety assessment.
Statistical Analysis
Continuous data are summarized by mean, SD, median, 
first and third quartile, and minimum and maximum. 
Categorical data are presented by absolute and relative 
frequencies (n and %) or contingency tables and, where 
relevant, with their 95% confidence interval (CI) limits.
The presence/absence of ≥1 WHC was analyzed also by 
means of a logistic regression model, considering as covari-
ates the type of induction (basiliximab vs ATG), capacity 
of the center (>10 vs ≤10 patients), diabetes mellitus (yes vs 
no), age at transplantation, and BMI (<25 vs ≥25 kg/m2).
The primary analysis was performed on the safety 
population.
The time to event was analyzed by means of a Cox 
model, considering the same covariate used in the logis-
tic regression model. The hazard ratio (HR) with a 95% 
CI was presented. Kaplan-Meier curves of time were also 
calculated. Changes in renal function were analyzed by the 
ANCOVA model, considering the same covariate used in 
the logistic regression model.
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For the comparison of proportion, the chi-square test or 
the Fisher exact test was used, while the Wilcoxon test was 
used for continuous nonnormally distributed data.
All the analysis were produced using 9.4 SAS for 
Windows.
In order to manage the missing data, patients who dis-
continued the study before reaching the endpoint, those 
who discontinued EVR for any reason, and those with 
missing information about WHC were considered fail-
ures, according to the worst-case scenario approach, and 
successes, according to the best-case scenario approach 
(Sensitivity Analysis).
RESULTS
Study Population
Three hundred ninety-nine patients were screened; of 
these, 394 were randomized (IE  =  197; DE  =  197), and 
383 (98.2%) received ≥1 dose of the study drug and were 
included in both the intent-to-treat and the safety popu-
lations. Two patients were treated differently than the 
assigned treatment arm; 336 patients out of 383 (87.7%) 
completed the 3-month study (IE  =  181; DE  =  155); of 
these, 310 (80.9%) (IE = 161 [81.7%]; DE = 149 [75.6%]) 
completed the CORE study on treatment. In particu-
lar, 12 patients in the IE arm discontinued the study due 
to graft loss (n  =  4); consent withdrawn (n  =  3); death 
(n = 2); administrative reasons (n = 2); and lost to follow-
up (n = 1). In the DE arm, 35 patients discontinued due 
to protocol violation (total n = 28; due to a nonswitch to 
EVR for unknown reason n = 25; clinical reasons n = 2; 
error n = 1); death (n = 3); consent withdrawn (n = 2); graft 
loss (n = 1); or administrative reasons (n = 1). In the IE 
arm, 32 patients (16.2%) discontinued EVR at 3 months, 
mainly due to AEs (n = 24, 12.4%), while in the DE arm, 
only 12 patients (7.4%) required EVR discontinuation. 
Three hundred seven patients had their 12-month follow-
up visit (IE = 159 [82.4%]; DE = 148 [77.9%]) (Figure 2).
Demographics on recipients’ and donors’ baseline char-
acteristics of the 2 treatment arms are detailed in Table 1.
In the DE arm, the switch to EVR was successful in 161 
(84.7%) (median time to switch, 29 d [range, 24–62 d]).
At the end of CORE study, the majority of patients in 
the IE arms were compliant with the C0–EVR protocol 
(namely 76.2%, 80.4%, and 79.4% after 14 ± 4 and 28 ± 
4 days and 3 mo, respectively), while 10% showed blood 
levels <3–8 ng/mL and 10% above such levels. In the DE 
arm, 91.8% of patients had levels within range, while in 
8.2% of them, levels were below 3–8 ng/mL.
Primary Endpoint: WHCs
Considering the worst-case scenario, the 3-month rate 
of patients without WHC in the IE and DE arms was 0.68 
(95% CI, 0.62-0.75) versus 0.62 (95% CI, 0.55-0.68) 
(log-rank test: P  =  0.56) (Figure  3). This accounted for 
a 16% increase in the relative risk for WHC occurrence 
in the DE arm (HR, 1.16; 95% CI, 0.81-1.64; P = 0.42). 
The results were confirmed considering the best-case sce-
nario (Figure 4); drop out patients seem to have a different 
impact on the results, according to the above scenarios, 
FIGURE 2. Patient disposition. EVR, everolimus; ITT, intent-to-treat; pts, patients.
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especially in the DE arm, where 12.6% did not switch to 
EVR and therefore dropped out of the study (Table 2).
The most frequent complications were as follows: fluid 
collection (IE = 32 [16.6%] vs DE = 33 [17.4%]; P = 0.84) 
and lymphocele (IE = 20 [10.4%] vs DE = 30 [15.8%]; 
P = 012). A lower percentage of patients experienced lym-
phorrhea (IE = 5 [2.59%] vs DE = 13 [6.84%]; P = 0.05) 
and hematoma (IE  =  14 [7.25%] vs DE  =  5 [2.63%]; 
P = 0.04) (Table 3).
Similar results were observed over the entire follow-up 
period (12 mo), considering the worst- (Figure 5) and best-
case (Figure 6) scenario (Table 2).
After 12 months, the DE arm showed a greater inci-
dence of lymphocele versus the IE arm (IE = 21 [10.88%] 
vs DE = 35 [18.42%]; P = 0.04); conversely, the occurrence 
of hematoma was greater in the IE arm (IE = 15 [7.77%] 
vs DE = 5 [2.63%]; P = 0.02) (Table 3).
Considering the CORE phase and worst-case scenario, 
the multivariate Cox model identified ATG as a risk factor 
for the occurrence of WHC (HR, 1.62; 95% CI, 1.06-2.46; 
P = 0.02); however, these findings were not confirmed in 
the best-case scenario approach (HR, 1.47; 95% CI, 0.93-
2.33; P = 0.10). BMI <25 kg/m2 was identified as a predic-
tor of WHC-free status at 12 months, both in the worst 
(HR, 0.66; 95% CI, 0.47-0.92; P = 0.02) and best-case sce-
nario (HR, 0.64; 95% CI, 0.44-0.93; P = 0.02) (Table 4).
Secondary Efficacy Endpoints
At 3 months, considering the worst-case scenario, the 
composite efficacy treatment failure (ie, death/graft loss/
BPAR) was 22 in the IE arm (11.4%) versus 40 (21.0%) in 
the DE arm (log-rank: P = 0.06; HR, 1.54; 95% CI, 0.90-
2.64; P  = 0.11). Fitting the best-case scenario approach, 
the treatment failure rate was lower in both arms (IE = 16 
[8.3%] vs DE = 13 [6.8%]; log-rank: P = 0.57; HR, 0.63; 
TABLE 1.
Demographics and baseline recipient and donor charac-
teristics (safety population)
Recipient
IE
N = 193
DE
N = 190
Age (y) at screening, mean (SD) 51.46 (11.37) 51.19 (12.29)
Male (%) 134 (69.4) 132 (69.5)
Presence of diabetes mellitus (%) 17 (8.8) 17 (9.0)
BMIa, mean (SD) 24.65 (3.28) 24.41 (3.29)
BMIa ≥25 (%) 89 (46.6) 86 (46.5)
End-stage disease leading to KT (%)   
 Glomerulonephritis/glomerular disease 56 (29.0) 57 (30.0)
 Polycystic disease 45 (23.3) 40 (21.0)
 Hypertension/nephrosclerosis 32 (16.6) 17 (9.0)
 Pyelonephritis 5 (2.6) 3 (1.6)
 Diabetes mellitus 5 (2.6) 5 (2.6)
 Unknown origin 21 (10.9) 38 (20.0)
 Other 29 (15.0) 30 (17.8)
PRA (%), mean (SD) 1.33 (6.57) 2.46 (8.13)
Cold ischemia time (h), mean (SD)b 12.31 (4.90) 12.39 (5.50)
Induction therapy (%)   
 Basiliximab 152 (78.8) 157 (82.6)
 ATG 37 (19.2) 31 (16.3)
 None 4 (2.1) 2 (1.0)
Donor   
Age (y), mean (SD) 52.77 (15.34) 53.21 (14.39)
Male (%) 100 (51.8) 94 (49.5)
Living donor (%)   
 Related 5 (2.6) 6 (3.2)
 Unrelated 3 (1.5) 5 (2.6)
aIE: N = 191; DE: N = 185.
bCold ischemia time considered only in deceased donor.
ATG, antithymocyte globuline; BMI, body mass index; DE, delayed everolimus; IE, immediate 
everolimus; KT, kidney transplantation; SD, standard deviation; PRA, panel reactive antibodies.
FIGURE 3. Kaplan-Meier curve of time to first wound healing complication during the first 3 mo after transplantation: worst-case 
scenario approach (intent-to-treat population). Nr. at Risk, number at risk.
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95% CI, 0.29-1.39; P = 0.25). The graft loss in IE was due 
to acute rejection (n = 3); primary nonfunction (n = 1); or 
graft artery thrombosis (n = 1), while in DE, it was due 
to renal vein thrombosis. The difference between the best- 
and the worst-case scenario approach was due to a dif-
ference between the arms in the dropout rate, since in the 
DE arm, 12% (24/190) of patients did not switch to EVR. 
Similar results were observed considering the 12-month 
follow-up period (Table 5).
The 1-year patient and graft survival rates, in the IE and 
DE arms, were 99.0% versus 98.4% (log-rank: 0.6565) 
and 96.9% versus 98.4% (log-rank: 0.3337), respectively 
(Figures  7 and 8). Five patients died during the CORE 
study (IE = 2; DE = 3), due to acute myocardial infarction 
(IE = 1; DE = 1); cardiovascular accident (IE = 1; DE = 1); 
and cerebral hemorrhage (DE  =  1). None of the deaths 
were considered by the investigators to be EVR related.
Considering the entire study period, no difference was 
observed either in BPAR (IE  =  19 [9.84%] vs DE  =  16 
[8.42%]; P = 0.61) or in DGF (IE = 46 [23.8%] vs DE = 60 
[31.6%]; P = 0.12) (Table 5).
No differences in renal function and proteinuria were 
observed at months 3 and 12 (Table 6).
Relevant concomitant medications are listed in Table 7.
Adverse Events
There were no differences between the arms with regard 
to patients who experienced ≥1 AE/serious AE/infection 
or in the number of patients who discontinued treatment 
due to AE/infection (Table  8). Specifically, 171 patients 
(88.6%) in the IE arm versus 174 (91.6%) in the DE arm 
experienced ≥1 AE (P = 0.42); of these AEs, 71 (36.8%) 
in the IE arm and 53 (27.9%) in the DE arm were con-
sidered EVR related (P = 0.06). The shorter exposure to 
FIGURE 4. Kaplan-Meier curve of time to first wound healing complication during the first 3 mo after transplantation: best-case 
scenario approach (intent-to-treat population).
TABLE 2.
WHC at 3 and 12 mo: ITT population
 
IE
N = 193
DE
N = 190
Log-rank 
Cox proportional  
hazard model: DE vs IE
N (%) 95% CI N (%) 95% CI HR (95% CI) P
3 mo: worst case
 Patients without WHC 132 (68.4) 62-75 117 (61.6) 55-68 0.5604 1.16 (0.81-1.64) 0.4156
3 mo: best case
 Patients without WHC 136 (70.5) 64-77 136 (71.6) 65-78 0.7685 0.98 (0.67-1.43) 0.8997
12 mo: worst case
 Patients without WHC 127 (65.8) 59-72 113 (59.5) 52-66 0.3252 1.21 (0.86-1.69) 0.2757
12 mo: best case
 Patients without WHC 131 (67.9) 61-74 132 (69.5) 63-76 0.7543 0.97 (0.67-1.40) 0.8667
In the Cox proportional hazard model, the following confounding factors were included: age at KT, BMI (<25 vs ≥25), center dimension (>10 vs ≤10), presence of diabetes mellitus, and induction (ATG 
vs basiliximab).
ATG, antithymocyte globuline; BMI, body mass index; CI, confidence interval; DE, delayed everolimus; HR, hazard ratio; IE, immediate everolimus; ITT, intent-to-treat; KT, kidney transplantation; WHC, 
wound healing complications.
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EVR in the DE arm and the fact that 12% of patients did 
not switch to EVR may have contributed to this result. 
Patients who showed ≥1 serious AE/infection in the IE 
versus DE arm were 73 (37.8%) and 61 (32.1%), respec-
tively (P = 0.29). Patients who permanently or temporarily 
discontinued EVR due to AEs/infections in the IE versus 
DE arm were 29 (15.0%) versus 21 (11.1%) (P = 0.32) 
and 18 (9.3%) versus 23 (12.1%) (P = 0.47), respectively.
Thirty-three patients experienced ≥1 cytomegalovirus 
infection (IE = 14 [7.2%] and DE = 19 [10%]; P = 0.33). 
Of them, only 6 recipients (14%) received cytomegalovirus 
prophylaxis (P = 0.19). Eleven patients experienced new 
onset of diabetes mellitus (IE = 5 [3.1%] vs DE = 6 [4.1%]; 
P = 0.76) (Table 8).
Considering the overall cohort, 1 patient (in the DE 
arm) experienced a new occurrence of renal cancer.
DISCUSSION
The immediate introduction of EVR after KT does not 
increase the risk of WHC. In fact, in our population, the 
DE use was not associated with a decreasing risk of WHC 
versus those who received IE. Both the worst- and best-
case scenario of this analysis—which were fitted to avoid 
any bias due to missing information—clearly showed that 
no difference in terms of WHC was identified between 
the arms. The immediate use of EVR in the study period 
resulted in a WHC-free rate between 68% and 70% 
(considering the worst- and best-case approach) versus 
62% and 72% in those who received a delayed dose; the 
most common complications in IE were fluid collection 
(17%), lymphocele (10%), and wound dehiscence (6%), 
which were not different at 3 months from the DE arm. 
Interestingly, at 12 months, the DE arm showed a higher 
incidence of lymphocele, while hematoma seemed to be 
more frequent in the IE arm. The risk of WHC increased 
by >60% in case of use of ATG induction, confirming what 
already stated by Pourmand et al32 in 2012, suggesting that 
Ab-IL2-R (namely Basiliximab) should be an induction of 
choice in mTORi-based IS (also in the delayed introduc-
tion protocol). The risk also increases in obese recipients 
(BMI, >30 kg/m2)27; in fact, in our series, BMI <25 kg/
m2 proved to have a protective role on WHC; therefore, 
we suggest to avoid a combination therapy of ATG and 
mTORi, especially in overweight recipients to decrease the 
“synergistic effects” on WHC.
TABLE 3.
Wound healing complication details at 3 and 12 mo: ITT 
population
 
IE
N = 193
DE
N = 190
PN (%) N (%)
Occurred within 3 mo    
 Lymphorrhea 5 (2.6) 13 (6.8) 0.0493
 Hematoma 14 (7.2) 5 (2.6) 0.0373
 Lymphocele 20 (10.4) 30 (15.8) 0.1150
 Fluid collection 32 (16.6) 33 (17.4) 0.8372
 Wound dehiscence 11 (5.7) 5 (2.6) 0.1335
 Wound infections 7 (3.6) 6 (3.2) 0.7999
 Incisional hernia 0 3 (1.2) 0.1211
Occurred within 12 mo    
 Lymphorrhea 6 (3.1) 13 (6.8) 0.0925
 Hematoma 15 (7.8) 5 (2.6) 0.0238
 Lymphocele 21 (10.9) 35 (18.4) 0.0368
 Fluid collection 34 (17.6) 37 (19.5) 0.6401
 Wound dehiscence 12 (6.2) 5 (2.6) 0.0884
 Wound infections 7 (3.6) 6 (3.2) 0.7999
 Incisional hernia 2 (1.0) 3 (1.6) 0.6834
P values were calculated by means of a chi-square test except for hernia, where the Fisher exact 
test was used.
DE, delayed everolimus; IE, immediate everolimus; ITT, intent-to-treat.
FIGURE 5. Kaplan-Meier curve of time to first wound healing complication during the 12 mo after transplantation: worst-case scenario 
approach (intent-to-treat population).
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Even if no robust data had previous showed the clear 
role of mTORi on WHC in the KT setting, these results 
seem to be consistent with the preliminary issues and 
previously mentioned CALLISTO study, in which no 
difference was observed in the incidence or severity of 
WHC in KT recipients receiving either micophenolate 
mofetil (MMF) or EVR as de novo immunosuppressive 
drug.28
These findings, on the contrary, differ from the stud-
ies on sirolimus-based IS, since sirolimus seems to lead to 
WHC following KT17,19-22; the intriguing question thus 
arises as to why a difference may potentially exist between 
each other. Pharmacokinetic variations (higher bioavail-
ability and shorter half-life of EVR)33-35 or the loading 
doses and high exposure level of sirolimus immediately 
after KT may partly contribute to explaining the difference 
between the drugs. The high sirolimus exposure (namely 
C0, 8–30 ng/mL) in the first clinical experiences and asso-
ciation with MPA in CNI-free protocol immediately after 
transplantation can explain the unfavorable effect on 
wound healing.26
In 2013, Cooper et al36 showed that the higher blood 
level of EVR (namely >8 ng/mL) was also associated 
with an increasing risk (HR, 1.69; 95% CI, 1.20-2.38; 
P = 0.002) of WHC and the initial dose of 1.5 mg seems to 
be more protective than 3 mg with regard to WHC. Even if 
the present study has not explored the role of EVR blood 
levels on the incidence of WHC (only 10% of patients in 
the IE arm were above 3–8 ng/mL), we are strongly con-
vinced that a dose adjustment aimed at maintaining a 
level between 3 and 8 ng/mL is fundamental to decrease or 
avoid the WHC.
The role of EVR on wound healing was also inves-
tigated in heart transplantation by the so-called 
EVERHEART study. Similar in study design to the pre-
sent trial, the study showed no superiority in terms of 
WHC in the DE arm; however, similarly to CALLISTO, 
the study was not powered for WHC only, but for 
composite end-points (ie, wound healing delays, peri-
cardial and pleural effusion, and renal insufficiency). 
Therefore, it was not fit to investigate the final role of 
EVR in wound healing.33
In the study period, treatment failure does not sig-
nificantly differ between the arms, but—when consider-
ing the entire follow-up period (12 mo) and worst-case 
scenario—the immediate introduction of EVR seems to 
be superior, mostly in the graft loss and death rates; this 
results, however, should not be considered consistent, 
since they were not confirmed in the best-case scenario, 
so they cannot be considered conclusive. The 12-month 
BPAR rate in the IE arm was about 10%, therefore over 
10% less than in the CALLISTO study; this first of all 
confirms the high efficacy of the IE regimen, and also 
indicates that a high CNI-exposure immediately after 
KT can be safely avoided. This can also be confirmed 
by the rate of DGF; as a matter of fact, the IE and 
DE arms showed the same DGF rates (23% vs 30%); 
these results are completely in accordance with the 
CALLISTO study (25%) and larger Symphony study,19 
which reported DGF rates ranging between 32% and 
36% in CNI-treated recipients. From the current study 
and CALLISTO series, we can assert—albeit in disagree-
ment with other single experiences17,18,34,35—that the 
immediate use of mTORi does not influence the initial 
poor function in KT, a finding that was also confirmed 
by a similar renal function assessed between the treat-
ment arms throughout the follow-up.
Finally, permanent or temporary discontinuations 
of EVR were much less than in the CALLISTO study; 
indeed, in our series, the IE arm permanently discon-
tinued therapy in only 15% of the cases and tempo-
rarily in 9%, while in the DE arm, discontinuation 
occurred in about 12% of the cases. Controversially, 
the CALLISTO series reported a 25% discontinuation 
rate; this could be explained—as stated by the authors 
themselves—by the higher EVR trough levels reached 
FIGURE 6. Kaplan-Meier curve of time to first wound healing complication during the 12 mo after transplantation: best-case scenario 
approach (intent-to-treat population).
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in the DE arm in order, we argue, to avoid an allograft 
rejection after a decrease in the dose of CNI and the 
discontinuation of MPA.
The main drawback of the present study is that about 
20% of patients in the IE arm and 25% in the DE arm 
did not complete the CORE-phase study, resulting in a 
TABLE 4.
Cox multivariate analysis on the main risk factors influencing the WHC
Time point Approach Factors HR (95% CI) β estimate (SE) P
3 mo Worst case Age at transplantation (y)  0.01 (0.01) 0.4674
 BMI    
  <25 vs ≥25 kg/m2 0.76 (0.53-1.08)  0.1262
 Center size    
  >10 vs ≤10 patients 1.46 (0.78-2.73)  0.2353
 Diabetes mellitus    
  Yes vs no 0.91 (0.48-1.73)  0.7793
 Treatment arm    
  Delayed everolimus vs immediate everolimus 1.16 (0.81-1.64)  0.4156
 Type of induction    
    ATG (antithymocyte globulin) vs basiliximab (Simulect) 1.62 (1.06-2.46)  0.0246
12 mo Worst case Age at transplantation (y)  0.00 (0.01) 0.5488
 BMI    
  <25 vs ≥25 kg/m2 0.66 (0.47-0.92)  0.0159
 Center size    
  >10 vs ≤10 patients 1.40 (0.77-2.53)  0.2720
 Diabetes mellitus    
  Yes vs no 0.81 (0.43-1.52)  0.5035
 Treatment arm    
  Delayed everolimus vs immediate everolimus 1.21 (0.86-1.69)  0.2757
 Type of induction    
    ATG (antithymocyte globulin) vs basiliximab (Simulect) 1.47 (0.98-2.20)  0.0653
3 mo Best case Age at transplantation (y)  0.01 (0.01) 0.3828
 BMI    
  <25 vs ≥25 kg/m2 0.74 (0.50-1.08)  0.1214
 Center size    
  >10 vs ≤10 patients 1.42 (0.72-2.82)  0.3154
 Diabetes mellitus    
  Yes vs no 0.93 (0.48-1.82)  0.8312
 Treatment arm    
  Delayed everolimus vs immediate everolimus 0.98 (0.67-1.43)  0.8997
 Type of induction    
    ATG (antithymocyte globulin) vs basiliximab (Simulect) 1.47 (0.93-2.33)  0.0976
12 mo Best case Age at transplantation (y)  0.01 (0.01) 0.4389
 BMI    
  <25 vs ≥25 kg/m2 0.64 (0.44-0.93)  0.0184
 Center size    
  >10 vs ≤10 patients 1.58 (0.80-3.13)  0.1871
 Diabetes mellitus    
  Yes vs no 0.84 (0.43-1.64)  0.6161
 Treatment arm    
  Delayed everolimus vs immediate everolimus 0.97 (0.67-1.40)  0.8667
 Type of induction    
    ATG (antithymocyte globulin) vs basiliximab (Simulect) 1.40 (0.90-2.18)  0.1403
Cox analysis modeled the risk to the first wound healing complication during the 3- and 12-mo periods. Since the EVR dosage was set to 1.5 mg daily in all study populations (for both arms) and 80% 
of patients were within the protocol target blood levels range (namely 3–8 ng/mL), the multivariate Cox regression was not fitted, considering either the EVR set dose or EVR blood levels >8 ng/mL as a 
risk factor (too few cases to justify the analysis); a posthoc analysis of the incidence of wound events between patients out of C
0
-EVR target level (ie, above or below 3–8 ng/mL) at any time during the 
3 mo of the study vs patients who remained into target level at each time point (in both arms) showed no differences between patients’ target level IN vs target level OUT. The incidence of 3 mo BPAR 
rate/corticosteroid bolus use was 5% (n: 20/383; IE: 11; DE: 9); thus, it was not considered in the Cox model. According to the best-case scenario approach, “failure” (≥1 healing complication) consisted 
of one of the following cases: wound complication, missing information about wound complications for patients who discontinued the study due to “death” or “graft loss,” and study discontinuation 
due to “death” or “graft loss” for patients who did not attend the month 12 follow-up visit. According to the worst-case scenario, “failure” (≥1 healing complication) consisted of one of the following 
cases: wound complication, missing information about wound complications, and study discontinuation due to any reason for patients who did not undergo the month 12 follow-up visit. Failure time 
was defined by the date of first wound complication or that of last visit performed.
ATG, antithymocyte globuline; BMI, body mass index; BPAR, biopsy-proven acute rejection; C
0
, immunosuppression blood levels, before morning dose; CI, confidence interval; DE, delayed everolimus; 
EVR, everolimus; HR, hazard ratio; IE, immediate everolimus; WHC, wound healing complications.
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slightly decrease in the previous sample size powered for 
the aim of the study. In addition, patients were followed 
up to 3 months, and some WHCs (ie, lymphocele and 
incisional hernia) need more time to be evaluated con-
clusively. This limitations were managed adding a fol-
low-up at 12 months even if, during this observational 
period, patients were treated—as per clinical prac-
tice—in 22 different centers, and therefore, they were 
monitored less strictly than during the first 3 months. 
Furthermore, the article is not generalizable to all KT 
patients since it lack the presence of severe obese recipi-
ents that could sustain WHC.
Although the enrollment of a small proportion of liv-
ing KT donors could seem to be a limitation of the study, 
we think that it is representative of the real setting of KT 
in Italy37 without affecting the study end-points, since 
only 5% of the study cohort received a kidney from living 
donors.
In conclusion, treating patients with DE-based IS after 
KT does not decrease the risk of WHC after KT; hence, 
TABLE 5.
Secondary efficacy endpoint at 3 and 12 mo: ITT population
IE
N = 193
DE
N = 190 Log-rank
Cox proportional hazard 
model: DE vs IE
 N (%) 95% CI N (%) 95% CI P HR (95% CI) P
3 mo
 Treatment failure (worst-case scenario) 22 (11.4) 7-16 40 (21.0) 15-27 0.0591 1.54 (0.90-2.64) 0.1129
 Treatment failure (best-case scenario) 16 (8.3) 4-12 13 (6.8) 3-10 0.5731 0.63 (0.29-1.39) 0.2527
 BPAR 11 (5.7) 2-9 9 (4.7) 2-8 0.6539 0.74 (0.30-1.85) 0.5232
 D 2 (1.0) 0-2 3 (1.6) 0-3 0.6565 0.55 (0.05-6.30) 0.6326
 D/GL 7 (3.6) 1-6 4 (2.1) 0-4 0.3634 0.28 (0.06-1.34) 0.1116
 GL 5 (2.6) 0-5 1 (0.5) 0-2 0.1027 0.19 (0.02-1.61) 0.1269
12 mo
 Treatment failure (worst-case scenario) 31 (16.1) 11-21 48 (25.3) 19-31 0.0565 1.43 (0.90-2.27) 0.1291
 Treatment failure (best-case scenario) 25 (12.9) 8-18 21 (11.0) 7-16 0.5546 0.69 (0.37-1.27) 0.2302
 BPAR 19 (9.8) 6-14 16 (8.4) 4-12 0.6110 0.76 (0.38-1.52) 0.4338
 D 2 (1.0) 0-2 3 (1.6) 0-3 0.6565 0.55 (0.05-6.30) 0.6326
 D/GL 8 (4.1) 1-7 6 (3.2) 1-6 0.6085 0.48 (0.15-1.61) 0.2372
 GL 6 (3.1) 1-6 3 (1.6) 0-3 0.3337 0.49 (0.12-1.95) 0.3084
In the Cox proportional hazard model, the following confounding factors were included: age at KT, BMI (<25 vs ≥25), center dimension (>10 vs ≤10), presence of diabetes mellitus, and induction (ATG 
vs basiliximab).
ATG, antithymocyte globuline; BMI, body mass index; BPAR, biopsy-proven acute rejection; CI, confidence interval; D, death; DE, delayed everolimus; GL, graft loss; HR, hazard ratio; IE, immediate 
everolimus; ITT, intent-to-treat; KT, kidney transplantation.
FIGURE 7. Patient survival analysis during the first 12 mo after transplantation: Kaplan-Meier curve (intent-to-treat population).
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de novo EVR does not expose KT recipients to a higher 
risk of WHC and also maintains a good efficacy and safety 
profile. Further studies are needed to confirm the clear role 
of ATG on WHC, since in the current trial a risk factor 
was considered only when a worst-case scenario analysis 
was fitted.
FIGURE 8. Graft survival analysis during the first 12 mo after transplantation: Kaplan-Meier curve (intent-to-treat population).
TABLE 6.
Graft function
IE
N = 193
DE
N = 190 P
Follow-up: 3 mo    
 DGFa (%) 46 (23.8) 60 (31.6) 0.1232b
 Days of dialysis, mean (SD) 16.17 (22.8) 9.40 (13.05) 0.2261c
 eGFR–MDRD4 (mL/min), mean (SD) N = 187 N = 183  
  At M3 48.82 (23.9) 49.21 (22.7) –
  Changes vs baseline 38.64 (22.4) 39.13 (21.5) 0.9716d
 Serum creatinine (mg/dL), mean (SD) N = 187 N = 183  
  At M3 2.02 (1.8) 1.80 (1.0) –
  Changes vs baseline −4.79 (2.7) −5.13 (2.3) 0.1191d
 Proteinuria,e n/N (%) 8/141 (5.7) 8/138 (5.8) 0.07f
Follow-up: 12 mo    
 DGFa (%) 46 (23.8) 60 (31.6) 0.1232b
 Days of dialysis, mean (SD) 16.17 (22.8) 9.40 (13.05) 0.2261c
 eGFR–MDRD4 (mL/min), mean (SD) N = 151 N = 142  
  At M12 51.57 (19.3) 51.77 (20.7) –
  Changes vs baseline 41.26 (18.7) 41.56 (19.9) 0.7137d
 Serum creatinine (mg/dL), mean (SD) N = 151 N = 142  
  At M12 1.67 (1.0) 1.67 (0.8) –
  Changes vs baseline −4.96 (2.5) −5.22 (2.2) –
Proteinuria,e n/N (%) 9/116 (7.8) 11/115 (9.6) –
aDGF defined as kidney allograft rejection with final clinical diagnosis “DGF” or the presence of postoperative dialysis started during the first 7 d following the transplant.
bChi-square test.
c Wilcoxon test.
dNonparametric ANCOVA model taking into account the following covariates: eGFR at baseline, center size, diabetes mellitus, and age at KT.
eProteinuria was defined as value >1000 mg/d if assessed in urine collected in 24 h or a value >1.0 if measured on the urine protein/creatinine concentration ratio in a spot urine sample.
fWald test from logistic regression analysis, taking into account the following factors: age at KT and diabetes mellitus.
DE, delayed everolimus; DGF, delayed graft function; eGFR, estimated glomerular filtration rate; IE, immediate everolimus; KT, kidney transplantation; M, month; MDRD, modification of diet in renal 
diseases; SD, standard deviation.
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